AUG 18·SEC EDGARLow
Fisher Michal purchased $10K of CNSP
Fisher Michal purchased 2,000 shares of CNS Pharmaceuticals, Inc. (CNSP) at $5.00 on 2026-05-18.
StockNASDAQ · US · USDHealthcare · Biotechnology
$CNSP
CNS Pharmaceuticals, Inc.
Price · $CNSPvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
No SEC Form 4 filings for $CNSP in the last 30 days.
See all $CNSP insider activity →Top stories · $CNSPMore →
AUG 12·news.alphastreet.com
CNS Pharmaceuticals Releases Q2 2026 Financial Results
CNS Pharmaceuticals (CNSP) reported Q2 2026 results with a basic and diluted loss of $0.37 per share, wider than the expected $0.24, and a net loss of $2.6M. The company said the per-share loss improved 94.2% year over year versus Q2 2025. Analysts’ consensus cited 4 buys, 1 hold, 0 sells.
MAY 1·Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) details CEO transition, pay and ownership in 10-K/A
CNS Pharmaceuticals (CNSP) filed an amended annual report (10-K/A) to update information
CNSP sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning CNSP (CNS Pharmaceuticals, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CNSP coverage spans financial news, insider activity and earnings.
What's driving CNSP
A small, non-10b5-1 insider open-market purchase provides mild sentiment support but is unlikely to change fundamentals.
The quarter shows near-term earnings pressure but also a large year-over-year loss improvement, which can affect sentiment and near-term positioning.
The amended 10-K/A for CNS Pharmaceuticals updates executive compensation, ownership structure, and other corporate governance details. No immediate material financial impact is evident, but the updates may influence investor perception.
CNS Pharmaceuticals is shifting focus from glioblastoma to neurology and oncology pipelines amid financial distress and a going concern risk. The company's recent trial failure and limited cash runway suggest increased volatility and downside risk, but potential upside if new pipeline strategies succeed.
CNS Pharmaceuticals reported a substantial net loss of $15.85 million, primarily due to increased R&D expenses, which may pressure the stock price in the short term.
alphai scores every news story that mentions CNSP with an AI model for sentiment and relevance, and aggregates insider trades from CNS Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CNSP
Score
Fisher Michal purchased $10K of CNSP
Fisher Michal purchased 2,000 shares of CNS Pharmaceuticals, Inc. (CNSP) at $5.00 on 2026-05-18.
1 min read
CNS Pharmaceuticals Releases Q2 2026 Financial Results
CNS Pharmaceuticals (CNSP) reported Q2 2026 results with a basic and diluted loss of $0.37 per share, wider than the expected $0.24, and a net loss of $2.6M. The company said the per-share loss improved 94.2% year over year versus Q2 2025. Analysts’ consensus cited 4 buys, 1 hold, 0 sells.
2 min readCNS Pharmaceuticals (NASDAQ: CNSP) details CEO transition, pay and ownership in 10-K/A
CNS Pharmaceuticals (CNSP) filed an amended annual report (10-K/A) to update information
2 min readCNS Pharmaceuticals (NASDAQ: CNSP) pivots to neurology and oncology amid going concern risk
CNS Pharmaceuticals (NASDAQ: CNSP) is undergoing a strategic pivot, shifting its focus from solely glioblastoma to building an in-licensed pipeline in neurology and oncology. This change follows the Phase 2 trial failure of its legacy asset Berubicin to demonstrate superiority over lomustine in overall survival. The company faces a going concern risk, with cash flow projections indicating it can fund operations only into the third quarter of 2026, necessitating additional capital.
4 min readCNS Pharmaceuticals 10-K: Net loss $15.85M, Loss per share $35.75
CNS Pharmaceuticals reported a net loss of $15.85 million for the year, primarily due to increased research and development spending for clinical programs. The company's operating loss totaled $15.99 million, with a loss per basic share of $35.75 based on 443,369 weighted average shares outstanding. They also raised equity in 2025 to fund operations and trials through mid-2026.
2 min readCNS Pharmaceuticals appoints Lynne Kelley as CMO
CNS Pharmaceuticals (CNSP) has appointed Lynne Kelley, MD, FACS, as its new Chief Medical Officer (CMO). Dr. Kelley previously served as CMO at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals, and Senseonics. This appointment follows recent restructuring in the company's financial leadership.
2 min read